<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210170</url>
  </required_header>
  <id_info>
    <org_study_id>20071188</org_study_id>
    <secondary_id>P05299</secondary_id>
    <nct_id>NCT01210170</nct_id>
  </id_info>
  <brief_title>Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma</brief_title>
  <official_title>Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucocorticosteroids inhibit the disposal of organic cations by blocking organic cation
      transporters expressed by non-neuronal cells, thereby interfering with the inactivation of
      the organic cations by intracellular enzymes. Beta2-adrenergic agonists are organic cations,
      and the concentration of inhaled beta2-adrenergic agonists at beta2-adrenergic receptor sites
      on smooth muscle is likely to be increased by inhaled glucocorticosteroids (ICS) by the ICS'
      effect on the glucocorticosteroid-sensitive organic cation transporters. The investigators
      have shown in human airway vascular smooth muscle cells that the glucocorticosteroid action
      on organic cation uptake occurs within minutes, does not involve gene transcription or
      protein synthesis, is not mediated through classical steroid receptors, and is cell
      membrane-linked.

      In the present proposal, the investigators wish to use different single doses of mometasone,
      a clinically effective ICS, administered with or at different times before albuterol
      inhalation in subjects with moderate persistent asthma who are obstructed at the time of
      study.

      With this approach the investigators will test the hypothesis that a single inhalation of
      mometasone causes an acute, transient, dose-dependent potentiation of beta2-adrenergic
      bronchodilation.

      If the hypothesis that a single dose of mometasone acutely potentiates beta2-adrenergic
      bronchodilation is correct, the results would have a significant impact on treatment
      strategies involving ICSs and beta2-adrenergic agonists in patients with asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifteen non-smokers (males and females between the ages of 18 and 65 years) with
      physician-diagnosed moderate persistent asthma will be recruited for the study. The subjects
      will be allowed to use inhaled controller (including ICS) and rescue medication. At study
      entry, all asthmatic subjects must be clinically stable, and have a forced pre-bronchodilator
      one-second expired volume (FEV1) of &lt; 75% predicted.

      Approval for the protocol will be requested from the University of Miami Institutional Review
      Board. All subjects will provide written informed consent.

      Exclusion criteria:

        -  Cardiovascular disease and use of cardiovascular medications

        -  Pregnancy

        -  Use of oral controller medication for asthma (methylxanthines, systemic
           glucocorticosteroids, leukotriene modifiers)

        -  An acute respiratory infection within 4 weeks before enrollment.

      Each subject will make 8 visits to the research laboratory.

      Procedures:

      Visit 1 (screening visit): On this visit, after having signed the consent form, the subjects
      will perform spirometry before and 15 min after inhaling 180 µg albuterol from a HFA-MDI
      using a spacer.

      Visit 2-8:Subjects that qualify for the study will be asked to return for 7 more visits for
      the following treatment protocols:

        -  Inhalation of 400 µg mometasone 30 min before inhalation of 180 µg albuterol

        -  Inhalation of mometasone placebo 30 min before inhalation of 180 µg albuterol

        -  Simultaneous inhalation of 400 µg mometasone and 180 µg albuterol

        -  Simultaneous inhalation of mometasone placebo and 180 µg albuterol

      Systemic blood pressure, pulse, O2 saturation, spirometry and airway blood flow ( Qaw) will
      be measured before mometasone or placebo inhalation, and before and 15 min after albuterol
      inhalation except on the day when mometasone and albuterol are co-administered; on that day
      the measurements will be made before and 15 min after the mometasone/albuterol
      co-administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Albuterol-induced Change in FEV1</measure>
    <time_frame>15 minutes after albuterol inhalation</time_frame>
    <description>FEV1 will be measured before and after inhalation of 180 mcg albuterol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albuterol Induced Percent Change in Qaw</measure>
    <time_frame>change in Qaw 15 minutes after albuterol inhalation</time_frame>
    <description>Qaw will be measured before and 15 min after albuterol inhalation</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>mometasone 400 mcg - 30 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 400 mcg simultaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo- 30 min</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo simultaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 400 mcg - 60 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo- 60 min</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 200 mcg - 30 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 200 mcg - 60 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone 200 mcg simultaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomly assigned intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo inhalation before albuterol.</description>
    <arm_group_label>placebo- 30 min</arm_group_label>
    <arm_group_label>placebo simultaneous</arm_group_label>
    <arm_group_label>placebo- 60 min</arm_group_label>
    <other_name>Asmanex placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone 400 mcg</intervention_name>
    <description>mometasone inhalation before albuterol.</description>
    <arm_group_label>mometasone 400 mcg - 30 min</arm_group_label>
    <arm_group_label>mometasone 400 mcg simultaneous</arm_group_label>
    <arm_group_label>mometasone 400 mcg - 60 min</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone 200 mcg</intervention_name>
    <description>200ug mometasone before albuterol.</description>
    <arm_group_label>mometasone 200 mcg - 30 min</arm_group_label>
    <arm_group_label>mometasone 200 mcg - 60 min</arm_group_label>
    <arm_group_label>mometasone 200 mcg simultaneous</arm_group_label>
    <other_name>Asmanex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Fifteen non-smokers (males and females between the ages of 18 and 65
        years) with physician-diagnosed moderate persistent asthma and FEV1 &lt; 75% of predicted.

        Exclusion Criteria:Cardiovascular disease and use of cardiovascular medications, pregnancy,
        use of oral controller medication for asthma (methylxanthines, systemic
        glucocorticosteroids, leukotriene modifiers), an acute respiratory infection within 4 weeks
        before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Wanner</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Research Laboratory- University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <results_first_submitted>September 5, 2014</results_first_submitted>
  <results_first_submitted_qc>November 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2014</results_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Wanner</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>asthma,</keyword>
  <keyword>inhaled corticosteroids,</keyword>
  <keyword>airway blood flow,</keyword>
  <keyword>mometasone,</keyword>
  <keyword>albuterol</keyword>
  <keyword>spirometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>• Inhalation of 400 µg mometasone DPI 30 min before inhalation of 180 µg albuterol
Mometasone furoate: • Inhalation of 400 µg mometasone or placebo DPI 30 min before inhalation of 180 µg albuterol
• Inhalation of 400 µg mometasone or placebo DPI 60 min before inhalation of 180 µg albuterol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>• participant with asthma were enrolled in the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Albuterol-induced Change in FEV1</title>
        <description>FEV1 will be measured before and after inhalation of 180 mcg albuterol.</description>
        <time_frame>15 minutes after albuterol inhalation</time_frame>
        <population>As specified by the protocol, -60 minutes values were not to be analyzed if 200 mcg and 400 mcg of mometasone given 30 minutes before albuterol were determined to have no effect</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants Received 400 mcg Mometasone-30 Min</title>
            <description>mometasone 400 mcg 30 minutes before albuterol 180 mcg inhalation</description>
          </group>
          <group group_id="O2">
            <title>All Participants Received Placebo 30 Minutes Before Albuterol</title>
            <description>mometasone placebo 30 minutes before albuterol 180 mcg inhalation</description>
          </group>
          <group group_id="O3">
            <title>All Participants Received 400 mcg Mometasone Simultaneous</title>
            <description>inhalation of 400 mcg mometasone immediately before inhalation of 180 mcg albuterol</description>
          </group>
          <group group_id="O4">
            <title>All Participants Received Placebo Simultaneously With Albutero</title>
            <description>inhalation of mometasone placebo immediately before inhalation of 180 mcg albuterol.</description>
          </group>
          <group group_id="O5">
            <title>All Participants Received 200 mcg Mometasone-30 Min</title>
            <description>mometasone 200 mcg 30 minutes before inhalation of 180 mcg of albuterol</description>
          </group>
          <group group_id="O6">
            <title>All Participants Received 400 mcg -60 Min</title>
            <description>mometasone 400 mcg 60 minutes before inhalation of 180 mcg of albuterol</description>
          </group>
          <group group_id="O7">
            <title>All Participants Received Placebo -60 Min</title>
            <description>placebo 60 minutes before inhalation of 180 mcg of albuterol</description>
          </group>
          <group group_id="O8">
            <title>All Participants Received 200 mcg Mometasone Simultaneous</title>
            <description>inhalation of mometasone placebo immediately before inhalation of 180 mcg albuterol</description>
          </group>
          <group group_id="O9">
            <title>All Participants Received 200 mcg -60 Min</title>
            <description>mometasone 200 mcg 60 minutes before inhalation of 180 mcg of albuterol</description>
          </group>
        </group_list>
        <measure>
          <title>Albuterol-induced Change in FEV1</title>
          <description>FEV1 will be measured before and after inhalation of 180 mcg albuterol.</description>
          <population>As specified by the protocol, -60 minutes values were not to be analyzed if 200 mcg and 400 mcg of mometasone given 30 minutes before albuterol were determined to have no effect</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.04"/>
                    <measurement group_id="O2" value="0.18" spread="0.04"/>
                    <measurement group_id="O3" value="0.32" spread="0.04"/>
                    <measurement group_id="O4" value="0.20" spread="0.05"/>
                    <measurement group_id="O5" value="0.23" spread="0.04"/>
                    <measurement group_id="O6" value="NA">Prespecified data were not analyzed due to the -30min results</measurement>
                    <measurement group_id="O7" value="NA">were not analyzed due to the -30min results</measurement>
                    <measurement group_id="O8" value="NA">were not analyzed due to the -30min results</measurement>
                    <measurement group_id="O9" value="NA">were not analyzed due to the -30min results</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albuterol Induced Percent Change in Qaw</title>
        <description>Qaw will be measured before and 15 min after albuterol inhalation</description>
        <time_frame>change in Qaw 15 minutes after albuterol inhalation</time_frame>
        <population>As specified by the protocol, -60 minutes values were not to be analyzed if 200 mcg and 400 mcg of mometasone given 30 minutes before albuterol were determined to have no effect</population>
        <group_list>
          <group group_id="O1">
            <title>400 mcg Mometasone 30 Minutes Before Albuterol</title>
            <description>• Inhalation of 400 µg mometasone 30 min before inhalation of 180 µg albuterol</description>
          </group>
          <group group_id="O2">
            <title>Mometasone Placebo 30 Minutes Before Albuterol</title>
            <description>Inhalation of mometasone placebo 30 min before inhalation of 180 µg albuterol</description>
          </group>
          <group group_id="O3">
            <title>400 mcg Mometasone and Albuterol Simultaneously</title>
            <description>inhalation of 400 mcg mometasone immediately before inhalation of 180 mcg albuterol.</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Placebo and Albuterol Simultaneously</title>
            <description>inhalation of mometasone placebo immediately before inhalation of 180 mcg albuterol.</description>
          </group>
          <group group_id="O5">
            <title>400 mcg Mometasone 60 Minutes Before Albuterol</title>
            <description>Inhalation of 400 µg mometasone 60 min before inhalation of 180 µg albuterol</description>
          </group>
          <group group_id="O6">
            <title>Mometasone Placebo 60 Minutes Before Albuterol</title>
            <description>Inhalation of mometasone placebo 60 min before inhalation of 180 µg albuterol</description>
          </group>
          <group group_id="O7">
            <title>200 mcg Mometasone and Albuterol Simultaneously</title>
            <description>inhalation of 200 mcg mometasone immediately before inhalation of 180 mcg albuterol</description>
          </group>
          <group group_id="O8">
            <title>200 mcg Mometasone 60 Minutes Before Albuterol</title>
            <description>Inhalation of 200 µg mometasone 60 min before inhalation of 180 µg albuterol</description>
          </group>
          <group group_id="O9">
            <title>200 mcg Mometasone 30 Minutes Before Albuterol</title>
            <description>Inhalation of 200 µg mometasone 30 min before inhalation of 180 µg albuterol</description>
          </group>
        </group_list>
        <measure>
          <title>Albuterol Induced Percent Change in Qaw</title>
          <description>Qaw will be measured before and 15 min after albuterol inhalation</description>
          <population>As specified by the protocol, -60 minutes values were not to be analyzed if 200 mcg and 400 mcg of mometasone given 30 minutes before albuterol were determined to have no effect</population>
          <units>percent change in Qaw</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="15"/>
                <count group_id="O9" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="3"/>
                    <measurement group_id="O2" value="0" spread="3"/>
                    <measurement group_id="O3" value="30" spread="7"/>
                    <measurement group_id="O4" value="-2" spread="3"/>
                    <measurement group_id="O5" value="NA">data not analyzed</measurement>
                    <measurement group_id="O6" value="NA">data not analyzed</measurement>
                    <measurement group_id="O7" value="NA">data not analyzed</measurement>
                    <measurement group_id="O8" value="NA">data not analyzed</measurement>
                    <measurement group_id="O9" value="NA">data not analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Participants</title>
          <description>Simultaneous inhalation of 400 µg mometasone DPI and 180 µg albuterol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Wanner, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305) 243-2568</phone>
      <email>awanner@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

